source
- Alphabet’s GV tops biotech corporate investors with $5.23 billion in deals since 2025Alphabet’s venture arm GV has become the largest corporate spender in biotech, investing a cumulative $5.23 billion across 20 deals since the start of 2025. The total outlay exceeds the combined v…
- Verdiva ends mid-stage study of oral GLP-1 amid ‘market evolution’The candidate is an oral version of ecnoglutide, a subcutaneous formulation of which is approved in China for type 2 diabetes and weight management. Pfizer owns commercialization rights for ecnoglu…BioSpace · 16d ago↗ source
- Pfizer strikes over $500M partnership with Enodia to develop Sec61-targeting small-molecule drugs